Literature DB >> 25313793

Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.

Rowena E Johnston1, Mary M Heitzeg.   

Abstract

This systematic review was undertaken to determine the extent to which adult subjects representing sex (female), race (nonwhite), and age (>50 years) categories are included in clinical studies of HIV curative interventions and thus, by extension, the potential for data to be analyzed that may shed light on the influence of such demographic variables on safety and/or efficacy. English-language publications retrieved from PubMed and from references of retrieved papers describing clinical studies of curative interventions were read and demographic, recruitment year, and intervention-type details were noted. Variables of interest included participation by sex, age, and race; changes in participation rates by recruitment year; and differences in participation by intervention type. Of 151 publications, 23% reported full demographic data of study enrollees, and only 6% reported conducting efficacy analyses by demographic variables. Included studies recruited participants from 1991 to 2011. No study conducted safety analyses by demographic variables. The representation of women, older people, and nonwhites did not reflect national or international burdens of HIV infection. Participation of demographic subgroups differed by intervention type and study location. Rates of participation of demographic groups of interest did not vary with time. Limited data suggest efficacy, particularly of early therapy initiation followed by treatment interruption, may vary by demographic variables, in this case sex. More data are needed to determine associations between demographic characteristics and safety/efficacy of curative interventions. Studies should be powered to conduct such analyses and cure-relevant measures should be standardized.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25313793      PMCID: PMC4287187          DOI: 10.1089/AID.2014.0205

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  118 in total

1.  Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries.

Authors:  Jane Greig; Esther C Casas; Daniel P O'Brien; Edward J Mills; Nathan Ford
Journal:  AIDS       Date:  2012-07-31       Impact factor: 4.177

2.  Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction.

Authors:  Lourdes Arruvito; Marianela Sanz; Alison H Banham; Leonardo Fainboim
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

3.  Global distribution of the CCR5 gene 32-basepair deletion.

Authors:  J J Martinson; N H Chapman; D C Rees; Y T Liu; J B Clegg
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  HIV providers' perceptions of and attitudes toward female versus male patients.

Authors:  Oni J Blackstock; Mary Catherine Beach; P Todd Korthuis; Jonathan A Cohn; Victoria L Sharp; Richard D Moore; Somnath Saha
Journal:  AIDS Patient Care STDS       Date:  2012-09-14       Impact factor: 5.078

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells.

Authors:  Susana N Asin; Alysha M Heimberg; Susan K Eszterhas; Christiane Rollenhagen; Alexandra L Howell
Journal:  AIDS Res Hum Retroviruses       Date:  2008-05       Impact factor: 2.205

7.  Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

Authors:  Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Anton Pozniak; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Phillippa Easterbrook; Sara Gibbons; Saye Khoo
Journal:  Antivir Ther       Date:  2008

8.  Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication.

Authors:  J Judy Chang; Matt Woods; Robert J Lindsay; Erin H Doyle; Morgane Griesbeck; Ellen S Chan; Gregory K Robbins; Ronald J Bosch; Marcus Altfeld
Journal:  J Infect Dis       Date:  2013-06-10       Impact factor: 5.226

9.  Short-course antiretroviral therapy in primary HIV infection.

Authors:  Sarah Fidler; Kholoud Porter; Fiona Ewings; John Frater; Gita Ramjee; David Cooper; Helen Rees; Martin Fisher; Mauro Schechter; Pontiano Kaleebu; Giuseppe Tambussi; Sabine Kinloch; Jose M Miro; Anthony Kelleher; Myra McClure; Steve Kaye; Michelle Gabriel; Rodney Phillips; Jonathan Weber; Abdel Babiker
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

10.  Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Authors:  Steven A Yukl; Eli Boritz; Michael Busch; Christopher Bentsen; Tae-Wook Chun; Daniel Douek; Evelyn Eisele; Ashley Haase; Ya-Chi Ho; Gero Hütter; J Shawn Justement; Sheila Keating; Tzong-Hae Lee; Peilin Li; Danielle Murray; Sarah Palmer; Christopher Pilcher; Satish Pillai; Richard W Price; Meghan Rothenberger; Timothy Schacker; Janet Siliciano; Robert Siliciano; Elizabeth Sinclair; Matt Strain; Joseph Wong; Douglas Richman; Steven G Deeks
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

View more
  35 in total

1.  Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366.

Authors:  Karine Dubé; Lara Hosey; Kate Starr; Liz Barr; David Evans; Erin Hoffman; Danielle M Campbell; Jane Simoni; Jeremy Sugarman; John Sauceda; Brandon Brown; Karen L Diepstra; Catherine Godfrey; Daniel R Kuritzkes; David A Wohl; Rajesh Gandhi; Eileen Scully
Journal:  AIDS Res Hum Retroviruses       Date:  2020-04       Impact factor: 2.205

2.  Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Authors:  Boris Julg; Lynda Dee; Jintanat Ananworanich; Dan H Barouch; Katharine Bar; Marina Caskey; Donn J Colby; Liza Dawson; Krista L Dong; Karine Dubé; Joseph Eron; John Frater; Rajesh T Gandhi; Romas Geleziunas; Philip Goulder; George J Hanna; Richard Jefferys; Rowena Johnston; Daniel Kuritzkes; Jonathan Z Li; Udom Likhitwonnawut; Jan van Lunzen; Javier Martinez-Picado; Veronica Miller; Luis J Montaner; Douglas F Nixon; David Palm; Giuseppe Pantaleo; Holly Peay; Deborah Persaud; Jessica Salzwedel; Karl Salzwedel; Timothy Schacker; Virginia Sheikh; Ole S Søgaard; Serena Spudich; Kathryn Stephenson; Jeremy Sugarman; Jeff Taylor; Pablo Tebas; Caroline T Tiemessen; Randall Tressler; Carol D Weiss; Lu Zheng; Merlin L Robb; Nelson L Michael; John W Mellors; Steven G Deeks; Bruce D Walker
Journal:  Lancet HIV       Date:  2019-03-15       Impact factor: 12.767

3.  Screening and Enrollment by Sex in Human Immunodeficiency Virus Clinical Trials in the United States.

Authors:  Laura M Smeaton; Deborah Kacanek; Kateryna Mykhalchenko; Kristine Coughlin; Karin L Klingman; Susan L Koletar; Elizabeth Barr; Ann C Collier
Journal:  Clin Infect Dis       Date:  2020-08-22       Impact factor: 9.079

4.  Curing HIV: Moving Forward Faster.

Authors:  Marcella Flores; Rowena Johnston
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

5.  Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial.

Authors:  Markella V Zanni; Kathleen Fitch; Corinne Rivard; Laura Sanchez; Pamela S Douglas; Steven Grinspoon; Laura Smeaton; Judith S Currier; Sara E Looby
Journal:  HIV Clin Trials       Date:  2017-03

6.  Physician perceptions of HIV cure in China: A mixed methods review and implications for HIV cure research.

Authors:  Zachary Clarke Rich; Chuncheng Liu; Qingyan Ma; Fengyu Hu; Weiping Cai; Xiaoping Tang; Joseph David Tucker
Journal:  Asian Pac J Trop Dis       Date:  2015-08-14

Review 7.  Sexual dimorphism in HIV-1 infection.

Authors:  Anne Rechtien; Marcus Altfeld
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

8.  HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.

Authors:  Cecile D Lahiri; Nakita L Brown; Kevin J Ryan; Edward P Acosta; Anandi N Sheth; Cyra C Mehta; Jessica Ingersoll; Ighovwerha Ofotokun
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

9.  Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.

Authors:  Eileen P Scully; Monica Gandhi; Rowena Johnston; Rebecca Hoh; Ainsley Lockhart; Curtis Dobrowolski; Amélie Pagliuzza; Jeffrey M Milush; Christopher A Baker; Valerie Girling; Arlvin Ellefson; Robert Gorelick; Jeffrey Lifson; Marcus Altfeld; Galit Alter; Marcelle Cedars; Ajantha Solomon; Sharon R Lewin; Jonathan Karn; Nicolas Chomont; Peter Bacchetti; Steven G Deeks
Journal:  J Infect Dis       Date:  2019-03-15       Impact factor: 5.226

10.  Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.

Authors:  Karine Dubé; John Kanazawa; Chadwick Campbell; Cheriko A Boone; Allysha C Maragh-Bass; Danielle M Campbell; Moisés Agosto-Rosario; Jamila K Stockman; Dázon Dixon Diallo; Tonia Poteat; Mallory Johnson; Parya Saberi; John A Sauceda
Journal:  AIDS Res Hum Retroviruses       Date:  2021-05-31       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.